- $358.21bn
- $405.02bn
- $65.01bn
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals
Moderna retreats from 52-week high, wiping out $10 bln in value
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Pennsylvania secures $4 billion in investments, governor says
Advisory: Alerts wrongly tagged to Merck & Co withdrawn
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Factbox: Pharma sector doubles down on AI to slash costs, timelines
BioNTech's mRNA cancer therapy misses first goal in head and neck trial (updated)
BioNTech's mRNA cancer therapy misses first goal in head and neck trial
Brief: Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline And Continued Innovative Potential Of Existing Portfolio At ESMO 2026
Factbox: Major drugmakers turn to China for licensing deals
Street View: Merck eye disease drug matches Roche's therapy in study, analysts cautious
Brief: Merck Presents One-Year Results From The Pivotal Phase 2B/3 Brunello Study Evaluating Remigromig
Moderna shares rally after addition to Nasdaq 100; BofA raises price objective
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)